Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Revenues Rise 7 Percent as Net Loss More Than Doubles

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market on Wednesday that its first-quarter revenues rose 7 percent and its net loss more than doubled for the three months ended March 31.

The San Diego-based firm reported revenues of $10.6 million compared to $9.9 million in the first quarter of 2007. It said that the revenue increase was due primarily to an increase in sales of systems outside the US, consumable products sales, and growth in its contract research services group.

Sequenom earlier in April had cautioned that US sales for its flagship MassArray systems would be soft for the first quarter.

“Although this quarter’s sales performance in the United States was disappointing, we are pleased with our sales performance in Europe and the rest of the world,” said Sequenom President and CEO Harry Stylli in a statement. “We continue to monitor the United States market demand for MassArray systems and remain cautiously optimistic about the business through the remainder of 2008.”

Sequenom’s net loss jumped sharply to $8.6 million, or $.19 per share, compared to $3.8 million, or $.11 per share, in the first quarter of 2007.

The firm’s R&D expenses climbed 69 percent to  $4.9 million from $2.9 million year over year, while its SG&A costs rose 37.3 percent to $9.2 million from $6.7 million.

Sequenom finished the first quarter with $36.4 million in cash, cash equivalents, restricted cash, and short-term investments.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.